Scleroderma Lung Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

August 31, 1999

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Lung DiseasesPulmonary FibrosisSystemic SclerodermaScleroderma, Systemic
Interventions
DRUG

Cyclophosphamide

Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.

DRUG

Placebo

Matching gelcaps 25 mgs

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

The University of Texas Health Science Center, Houston

OTHER

NCT00004563 - Scleroderma Lung Disease | Biotech Hunter | Biotech Hunter